Reversing pathological remodelling of the bone marrow microenvironment in acute myeloid leukemia

Acute myeloid leukemia (AML) remains a formidable therapeutic challenge with the majority of older patients succumbing to disease progression despite aggressive treatment. Common reasons for lack of therapeutic efficacy in AML are complications related to marrow failure caused by progressive disease or early relapse after initial chemotherapy.